K Number
K132987
Device Name
COBRA FUNDUS CAMERA
Manufacturer
Date Cleared
2014-07-03

(282 days)

Product Code
Regulation Number
886.1120
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The CSO Cobra Fundus Camera is intended for taking digital images of a human retina with or without the use of mydriatic agent. The retinal image can be stored to an image filing device.
Device Description
Cobra is intended for taking digital images of a human retina with or without the use of a mydriatic agent. A function for retinal plane capturing is provided. The instrument is furnished with an integrated 5MP CCD camera, and uses one (1) white LED for flashing, one (1) IR led for alignment and Infrared acquisitioning. Cobra can be used with pupil diameters starting from 2.5 mm, and therefore can be used without the need for a mydriatic agent. Acquisition transfer is performed from the instrument to the accompanying PC via a Firewire cable.
More Information

Not Found

No
The document describes basic image acquisition and processing, but there is no mention of AI, ML, or any related concepts like deep learning or neural networks. The "image processing" mentioned appears to be standard digital image manipulation, not AI/ML-driven analysis.

No.
The Cobra Fundus Camera is intended for taking digital images of the human retina, which is a diagnostic function, not a therapeutic one. It does not treat or alleviate any condition.

No

Explanation: The device is intended for taking digital images of the human retina. While these images can be used as part of a diagnostic process by a healthcare professional, the device itself is described as an imaging tool and there is no mention of it performing any analysis or interpretation of those images to provide a diagnosis.

No

The device description explicitly mentions integrated hardware components like a 5MP CCD camera, white LED, and IR LED, and describes physical connections (Firewire cable). It also details performance testing related to electrical safety and electromagnetic compatibility, which are characteristic of hardware devices.

Based on the provided information, the CSO Cobra Fundus Camera is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
  • Cobra's Function: The Cobra Fundus Camera takes digital images of the human retina in vivo (within the living body). It does not analyze samples taken from the body.
  • Intended Use: The intended use is to capture images of the retina, not to perform diagnostic tests on biological samples.
  • Device Description: The description focuses on the imaging technology and how it captures images of the retina.
  • Anatomical Site: The anatomical site is the human retina, which is an internal part of the body being imaged directly.

Therefore, the CSO Cobra Fundus Camera falls under the category of medical imaging devices, not in vitro diagnostics.

N/A

Intended Use / Indications for Use

The CSO Cobra Fundus Camera is intended for taking digital images of a human retina with or without the use of mydriatic agent. The retinal image can be stored to an image filing device.

Product codes (comma separated list FDA assigned to the subject device)

HKI, NFJ

Device Description

Cobra is intended for taking digital images of a human retina with or without the use of a mydriatic agent. A function for retinal plane capturing is provided. The instrument is furnished with an integrated 5MP CCD camera, and uses one (1) white LED for flashing, one (1) IR led for alignment and Infrared acquisitioning.

Cobra can be used with pupil diameters starting from 2.5 mm, and therefore can be used without the need for a mydriatic agent. Acquisition transfer is performed from the instrument to the accompanying PC via a Firewire cable.

Mentions image processing

Cobra is an electromedical system that allows for digitally retrieving, acquiring and processing of a retinal image to the extent permitted by the laws and regulations for the exercise of their profession.

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

human retina

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Performance testing was conducted on the subject device and was found to perform as intended.

Cobra met all the requirements regarding to electrical safety (tests according to IEC 60601-1) and electromagnetic compatibility, according to IEC 60601-1-2.

Cobra met all the requirements of Group 1 instruments according to ISO 15004-2 in order to be in compliance to the standard.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K101628

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 886.1120 Ophthalmic camera.

(a)
Identification. An ophthalmic camera is an AC-powered device intended to take photographs of the eye and the surrounding area.(b)
Classification. Class II (special controls). The device, when it is a photorefractor or a general-use ophthalmic camera, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.

0

r

510(k) Summary 5

5.1 General information

General information
ManufacturerC.S.O. Srl
Via degli Stagnacci 12/E
50018 Badia a Settimo Scandicci (FI)
ITALY
Contact personPiet de Jong,
+39 055 722 1958
p.dejong@csoitalia.it
Date Prepared16 July 2013

Device information 5,2

Device information
Trade nameCobra Fundus Camera
Common NameFundus Camera
Classification NameOphthalmic Camera, AC-Powered
Regulation Number(s)21 CFR 886.1120
21 CFR 892.2050
Product Code(s)HKI, NFJ
PanelOphthalmic

5.3 Predicate devices

The Cobra Fundus Camera is compared for substantial equivalence with Kowa nonmyd WX Ophthalmic Camera, manufactured by Kowa Company Ltd, Tokyo, Japan (K101628).

5.4 Device description

Cobra is intended for taking digital images of a human retina with or without the use of a mydriatic agent. A function for retinal plane capturing is provided. The instrument is furnished with an integrated 5MP CCD camera, and uses one (1) white LED for flashing, one (1) IR led for alignment and Infrared acquisitioning.

Cobra can be used with pupil diameters starting from 2.5 mm, and therefore can be used without the need for a mydriatic agent. Acquisition transfer is performed from the instrument to the accompanying PC via a Firewire cable.

5.5 Intended use

Cobra is an electromedical system that allows for digitally retrieving, acquiring and processing of a retinal image to the extent permitted by the laws and regulations for the exercise of their profession.

The instrument allows for a direct, 'live' monitoring on the computer screen, and capturing also in cases where the pupil diameter starts from 2.5 mm.

1

5.6 Substantial equivalence

In accordance with the predicate device standards tests have been executed, resulting in the same technological characteristics.

Cobra met all the requirements regarding to electrical safety (tests according to IEC 60601-1)

Cobra met all the requirements to ensure electromagnetic compatibility, according to IEC 60601-1-2.

Cobra met all the requirements of Group 1 instruments according to ISO 15004-2 in order to be in compliance to the standard.

Concerning software validity of the CSO software, an evaluation was made based on FDA guidance, Guidance for the content of premarket submissions for software contained in medical devices, was performed.

The validation of Cobra acquisition software is performed as a part of a system function test. All functions are tested and confirmed working with traceability of remaining anomalies in a tracking system. Two tests were performed, one on functional level and one on system unit level. Both tests have been verified as meeting test criteria. All functional tests have been passed, as well as unit level tests.

The level of concern of Cobra acquisition software is moderate.

To evaluate biocompatibility, biocompatibility assessment was performed. All materials used are the same as other legally marked devices in US.

Cobra was evaluated for risk management in accordance with ISO 14971:2012, and met all requirements of the standard. The risk management of the device was deemed satisfactory.

The hardware interface for image transfer is different from the predicate device, but it cannot be considered critical to the intended therapeutic, diagnostic, prosthetic or surgical use of the device, nor can it affect the safety and effectiveness of the device when used as labeled.

Remaining risks will be noted in the user manual, so users will be able to avoid them.

It is concluded that Cobra is substantially equivalent with regards to functionality, design verification and intended use, to the identified predicate device already in interstate commerce within the USA, and that any differences that do exist have no effect on the safety and effectiveness of the device

5.7 Performance test

Performance testing was conducted on the subject device and was found to perform as intended.

Cobra met all the requirements regarding to electrical safety (tests according to IEC 60601-1) and electromagnetic compatibility, according to IEC 60601-1-2.

Cobra met all the requirements of Group 1 instruments according to ISO 15004-2 in order to be in compliance to the standard.

2

Concerning software validity of the Cobra acquisition software, an evaluation was made based on FDA guidance, Guidance for the content of premarket submissions for software contained in medical devices, was performed.

To evaluate biocompatibility, biocompatibility assessment was performed. All materials used are the same as other legally marked devices in US.

Cobra was evaluated for risk management in accordance with ISO 14971:2012, and met all requirements of the standard. The risk management of the device was deemed satisfactory.

Remaining risks will be noted in the user manual, so users will be able to avoid them.

In conclusion we can say that Cobra is substantially equivalent to the predicate device since the same requirements to referenced standards regarding safety and effectiveness were met.

3

Image /page/3/Picture/11 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. Inside the circle is a stylized symbol that resembles an abstract human figure with outstretched arms.

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

July 3, 2014

C.S.O. Srl. c/o Mr. Claude Berthoin Regulatory Consultant Thema USA 110 East Granada Blvd., Suite 209 Ormond Beach, FL 32716

Re: K132987

Trade/Device Name: Cobra Fundus Camera Regulation Number: 21 CFR 886.1120 Regulation Name: Ophthalmic Camera Regulatory Class: Class II Product Code: HKI, NFJ Dated: May 28, 2014 Received: June 2, 2014

Dear Mr. Berthoin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

4

Page 2 - Mr. Claude Berthoin

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://yww.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely vours.

Kesia Y. Alexander -S

for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

5

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

510(k) Number (if known) K132987

Device Name CSO Cobra Fundus Camera

Indications for Use (Describe)

The CSO Cobra Fundus Camera is intended for taking digital images of a human retina with or without the use of mydriatic agent. The retinal image can be stored to an image filing device.

Type of Use (Select one or both, as applicable)

2 Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.

FOR FDA USE ONLY

Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)

Leonid Livshitz -S 2014.06.27 13:20:03 -04'00'

This section applies only to requirements of the Paperwork Reduction Act of 1995.

"DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."